United States HR 1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.

Status: Introduced in House (as of 2025-02-06)

State: United States · Session: 119 · Bill: HR 1051

Sponsors: Nikki Budzinski

View United States HR 1051 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.